A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

NCT01702493 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Cap SRT2104
DRUG: Tab SRT2104 slow release
DRUG: Tab SRT2104 intermediate release
DRUG: Tab SRT2104 fast release
DRUG: Selected formulations of SRT2104 from Part 1
DRUG: Selected formulations of SRT2104 from Part 1 single alternative dose

Sponsor

Sirtris, a GSK Company